stockrow
Saturday 7 November 2026
Export LBRX’s income statement to Excel — free account
LB Pharmaceuticals Inc
LBRX Healthcare Biotechnology
- EPS
- +87.4%
- Free cash flow
- −579.0%
Quarter to June 2026, against a year earlier
42.01
3.92
+10.29%
Follow LBRX
Alert me
LB Pharmaceuticals Inc (LBRX) P/E ratio
LB Pharmaceuticals Inc has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NKTR Nektar Therapeutics compare | n/m |
| DRTS Alpha Tau Medical Ltd. compare | n/m |
| MNKD MannKind Corporation compare | n/m |
| URGN Urogen Pharma compare | n/m |
| SLN Silence Therapeutics PLC Sponsored ADR compare | n/m |
| GHRS GH Research PLC compare | n/m |
| LBRX LB Pharmaceuticals Inc | n/m |
| AVLN Avalyn Pharma Inc. compare | n/m |
| OMER Omeros Corporation compare | 9.8× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)